MiNK Therapeutics (INKT)
Develops allogeneic, off-the-shelf iNKT cell therapies for cancer and immune-mediated diseases.
$11.28
At close+0.33 (+3.01%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions23 holders · as of Mar 31, 2026 | 2.49% | 126.8K shares | |
| Insiders9 holders · as of Sep 2, 2026 | 4.09% | 208.7K shares | |
| Otherremainder | 93.42% | 4.77M shares |
5.10M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
23 holders · 126.8K shares · 5 new positions · 7 increased · 4 reduced · 7 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 59.4K | 1.16% | +59.4Knew | May 15, 2026 |
| Geode Capital Management, LLC | 17.3K | 0.34% | +3.1K | May 15, 2026 |
| Longbow Finance SA | 16.7K | 0.33% | 0 | May 12, 2026 |
| UBS Group AG | 15.2K | 0.30% | +5.7K | May 5, 2026 |
| Vanguard Fiduciary Trust Co | 8.3K | 0.16% | +8.3Knew | May 8, 2026 |
| BlackRock, Inc. | 6.2K | 0.12% | 0 | May 13, 2026 |
| Steward Partners Investment Advisory, LLC | 2.0K | 0.04% | +2.0Knew | May 8, 2026 |
| Paladin Partners, LLC | 1.0K | 0.02% | 0 | Jun 25, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 4, 2026 | Barbara Ryandirector | Sale · 2 lots | 1,500 | $12.76 | 21,969 |
| Mar 10, 2026 | Barbara Ryandirector | Sale · 3 lots | 1,300 | $15.40 | 20,406 |
| Mar 9, 2026 | Barbara Ryandirector | Sale | 200 | $10.17 | 21,706 |
| Mar 2, 2026 | Barbara Ryandirector | Sale | 100 | $10.83 | 21,906 |
| Feb 27, 2026 | Barbara Ryandirector | Sale | 400 | $10.86 | 22,006 |
CongressHouse and Senate disclosures
Not reported.